Natalizumab therapy for multiple sclerosis

Seminars in Neurology

Volumn 33, Issue 1, 2013, Pages 26-36

  Derfuss, Tobias ^a,b   Kuhle, Jens ^a,b,c   Lindberg, Raija ^b   Kappos, Ludwig ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB; PLACEBO;

ALLERGIC REACTION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTEGRINS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84878290669     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1343793     Document Type: Article

References (133)

1. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature: 1992; 356 6364 63 66
2. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell: 2002; 110 6 673 687 (Pubitemid 35283958)
3. Miller D. H., Khan O. A., Sheremata W. A., et al. International Natalizumab Multiple Sclerosis Trial Group A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2003; 348 1 15 23 (Pubitemid 36026342)
4. Tubridy N., Behan P. O., Capildeo R., et al. The UK Antegren Study Group The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology: 1999; 53 3 466 472 (Pubitemid 29382036)
5. Dalton C. M., Miszkiel K. A., Barker G. J., et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol: 2004; 251 4 407 413 (Pubitemid 38501297)
6. O'Connor P. W., Goodman A., Willmer-Hulme A. J., et al. Natalizumab Multiple Sclerosis Trial Group Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology: 2004; 62 11 2038 2043 (Pubitemid 38738218)
7. Rudick R. A., Stuart W. H., Calabresi P. A., et al. SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 911 923
8. Polman C. H., O'Connor P. W., Havrdova E., et al. AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 899 910
9. Miller D. H., Soon D., Fernando K. T., et al. AFFIRM Investigators MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology: 2007; 68 17 1390 1401 (Pubitemid 46659091)
10. Havrdova E., Galetta S., Hutchinson M., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol: 2009; 8 3 254 260
11. Radue E. W., Stuart W. H., Calabresi P. A., et al. SENTINEL Investigators Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci: 2010; 292 1-2 28 35
12. Cree B. A., Stuart W. H., Tornatore C. S., Jeffery D. R., Pace A. L., Cha C. H. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol: 2011; 68 4 464 468
13. Cree B. A., Al-Sabbagh A., Bennett R., Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol: 2005; 62 11 1681 1683 (Pubitemid 41626662)
14. Hutchinson M., Kappos L., Calabresi P. A., et al. AFFIRM and SENTINEL Investigators The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol: 2009; 256 3 405 415
15. Weinstock-Guttman B., Galetta S. L., Giovannoni G., et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol: 2012; 259 5 898 905
16. Rudick R. A., Miller D., Hass S., et al. AFFIRM and SENTINEL Investigators Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol: 2007; 62 4 335 346 (Pubitemid 350105948)
17. Goodman A. D., Rossman H., Bar-Or A., et al. GLANCE Investigators GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology: 2009; 72 9 806 812
18. O'Connor P., Polman C., Goodman A., et al. Efficacy and safety of natalizumab in the STRATA study Paper presented at: 61st Annual Meeting of the American Academy of Neurology.; April 25-May 2, 2009; Seattle, WA
19. O'Connor P. W., Goodman A., Kappos L., et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology: 2011; 76 22 1858 1865
20. Lanzillo R., Bonavita S., Quarantelli M., et al. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci: 2012
21. Prosperini L., Giannì C., Leonardi L., et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler: 2012; 18 1 64 71
22. Putzki N., Yaldizli O., Bühler R., Schwegler G., Curtius D., Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol: 2010; 63 2 101 106
23. Oturai A. B., Koch-Henriksen N., Petersen T., Jensen P. E., Sellebjerg F., Sorensen P. S. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol: 2009; 16 3 420 423
24. Holmén C., Piehl F., Hillert J., et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler: 2011; 17 6 708 719
25. Prosperini L., Fortuna D., Gianni C., Leonardi L., Pozzilli C. The diagnostic accuracy of static posturography in predicting accidental falls in people with multiple sclerosis. Neurorehabil Neural Repair: 2013; 27 1 45 52
26. Ghezzi A., Pozzilli C., Grimaldi L. M., et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology: 2010; 75 10 912 917
27. Papeix C., Vidal J. S., de Seze J., et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler: 2007; 13 2 256 259 (Pubitemid 46592781)
28. Warabi Y., Matsumoto Y., Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci: 2007; 252 1 57 61 (Pubitemid 44909191)
29. Kleiter I., Hellwig K., Berthele A., et al. Neuromyelitis Optica Study Group Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol: 2012; 69 2 239 245
30. Barnett M. H., Prineas J. W., Buckland M. E., Parratt J. D., Pollard J. D. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler: 2012; 18 1 108 112
31. Jacob A., Weinshenker B. G., Violich I., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol: 2008; 65 11 1443 1448
32. Leussink V. I., Lehmann H. C., Meyer zu Hörste G., Hartung H. P., Stüve O., Kieseier B. C. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol: 2008; 255 9 1436 1438
33. Fisher E., Lee J. C., Nakamura K., Rudick R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol: 2008; 64 3 255 265
34. Rinaldi F., Calabrese M., Seppi D., Puthenparampil M., Perini P., Gallo P. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler: 2012; 18 12 1760 1767
35. Gunnarsson M., Malmestrom C., Axelsson M., et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol: 2011; 69 1 83 89
36. Phillips J. T., Giovannoni G., Lublin F. D., et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler: 2011; 17 8 970 979
37. Belachew S., Phan-Ba R., Bartholomé E., et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol: 2011; 18 2 240 245
38. Balcer L. J., Galetta S. L., Calabresi P. A., et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology: 2007; 68 16 1299 1304 (Pubitemid 46625976)
39. Meuth S. G., Bittner S., Seiler C., Göbel K., Wiendl H. Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis. Mult Scler: 2011; 17 2 198 203
40. Mattioli F., Stampatori C., Bellomi F., Capra R. Natalizumab efficacy on cognitive impairment in MS. Neurol Sci: 2011; 31 03 321 323
41. Lang C., Reiss C., Mäurer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol: 2012; 67 3 162 166
42. Iaffaldano P., Viterbo R. G., Paolicelli D., et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS ONE: 2012; 7 4 e35843
43. Phillips J. T., O'Connor P. W., Havrdova E., et al. AFFIRM Investigators Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology: 2006; 67 9 1717 1718 (Pubitemid 44747962)
44. Hellwig K., Schimrigk S., Fischer M., et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol: 2008; 65 5 656 658 (Pubitemid 351679662)
45. Krumbholz M., Pellkofer H., Gold R., Hoffmann L. A., Hohlfeld R., Kümpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol: 2007; 64 9 1331 1333 (Pubitemid 47403090)
46. Calabresi P. A., Giovannoni G., Confavreux C., et al. AFFIRM and SENTINEL Investigators The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology: 2007; 69 14 1391 1403 (Pubitemid 47511460)
47. Sorensen P. S., Jensen P. E., Haghikia A., et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler: 2011; 17 9 1074 1078
48. Oliver B., Fernández O., Orpez T., et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler: 2011; 17 3 368 371
49. Jensen P. E., Koch-Henriksen N., Sellebjerg F., Sorensen P. S. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler: 2012; 18 10 1493 1499
50. Sorensen P. S., Koch-Henriksen N., Jensen P. E. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab. Neurology: 2011; 76 8 759 760
51. Zohren F., Toutzaris D., Klärner V., Hartung H. P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood: 2008; 111 7 3893 3895
52. Bonig H., Wundes A., Chang K. H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood: 2008; 111 7 3439 3441
53. Abbas M., Lalive P. H., Chofflon M., Simon H. U., Chizzolini C., Ribi C. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. Neurology: 2011; 77 16 1561 1564
54. Midaglia L., Rodriguez Ruiz M., Muñoz-García D. Severe haematological complications during treatment with natalizumab. Mult Scler: 2012; 18 11 1644 1646
55. Stosic M., De Jesus P., McCarthy J., Hutton G., Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology: 2011; 77 5 505 507
56. Mullen J. T., Vartanian T. K., Atkins M. B. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med: 2008; 358 6 647 648 (Pubitemid 351214309)
57. Bergamaschi R., Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler: 2009; 15 12 1532 1533
58. Vavricka B. M., Baumberger P., Russmann S., Kullak-Ublick G. A. Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler: 2011; 17 2 255 256
59. Laroni A., Bedognetti M., Uccelli A., Capello E., Mancardi G. L. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci: 2011; 32 1 181 182
60. Ismail A., Kemp J., Sharrack B. Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol: 2009; 256 10 1771 1772
61. Castela E., Lebrun-Frenay C., Laffon M., et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol: 2011; 147 1 72 76
62. Panzara M. A., Bozic C., Sandrock A. W. More on melanoma with transdifferentiation. N Engl J Med: 2008; 359 1 99 100, author reply 99-100
63. Schweikert A., Kremer M., Ringel F., et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol: 2009; 66 3 403 406
64. Bozic C., LaGuette J., Panzara M. A., Sandrock A. W. Natalizumab and central nervous system lymphoma: no clear association. Ann Neurol: 2009; 66 3 261 262
65. Kappos L., Bates D., Edan G., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol: 2011; 10 8 745 758
66. DeAngelis L. M. Primary central nervous system lymphoma imitates multiple sclerosis. J Neurooncol: 1990; 9 2 177 181
67. Ng S., Butzkueven H., Kalnins R., Rowe C. Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci: 2007; 14 11 1126 1129 (Pubitemid 47588932)
68. Ransohoff R. M. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum. Ann Neurol: 2009; 66 3 259 261
69. Schowinsky J., Corboy J., Vollmer T., Kleinschmidt-DeMasters B. K. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol: 2012; 123 5 751 752
70. Zecca C., Nessi F., Bernasconi E., Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology: 2009; 73 17 1418 1419
71. Shenoy E. S., Mylonakis E., Hurtado R. M., Venna N. Natalizumab and HSV meningitis. J Neurovirol: 2011; 17 3 288 290
72. Scheiss N., Zong J., Hayward G., Calabresi P. Reactivation of herpes virus in multiple sclerosis patients on natalizumab. Ther Clin Risk Manag: 2009; 5 585 594
73. Mulero P., Caminero A. B., Neri Crespo M. J., Fernández-Herranz R., Téllez Lara N. Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab. J Neuroimmunol: 2012; 243 1-2 103 105
74. Padgett B. L., Walker D. L., ZuRhein G. M., Eckroade R. J., Dessel B. H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet: 1971; 1 7712 1257 1260
75. Tan C. S., Koralnik I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol: 2010; 9 4 425 437
76. Jensen P. N., Major E. O. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol: 2001; 7 4 280 287 (Pubitemid 32894228)
77. Calabrese L. H., Molloy E. S., Huang D., Ransohoff R. M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum: 2007; 56 7 2116 2128 (Pubitemid 47173558)
78. Kleinschmidt-DeMasters B. K., Tyler K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med: 2005; 353 4 369 374 (Pubitemid 41132341)
79. Langer-Gould A., Atlas S. W., Green A. J., Bollen A. W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med: 2005; 353 4 375 381 (Pubitemid 41132342)
80. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med: 2005; 353 4 362 368 (Pubitemid 41132340)
81. Yousry T. A., Major E. O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med: 2006; 354 9 924 933
82. Lindå H., von Heijne A., Major E. O., et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med: 2009; 361 11 1081 1087
83. Bloomgren G., Richman S., Hotermans C., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med: 2012; 366 20 1870 1880
84. Chen Y., Bord E., Tompkins T., et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med: 2009; 361 11 1067 1074
85. Jilek S., Jaquiéry E., Hirsch H. H., et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol: 2010; 9 3 264 272
86. Rudick R. A., O'Connor P. W., Polman C. H., et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol: 2010; 68 3 304 310
87. Du Pasquier R. A., Stein M. C., Lima M. A., et al. JC virus induces a vigorous CD8. + cytotoxic T cell response in multiple sclerosis patients. J Neuroimmunol: 2006; 176 1-2 181 186
88. Warnke C., Smolianov V., Dehmel T., et al. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler: 2011; 17 2 151 156
89. Wenning W., Haghikia A., Laubenberger J., et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med: 2009; 361 11 1075 1080
90. Boster A., Hreha S., Berger J. R., et al. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol: 2009; 66 5 593 599
91. Kappos L., Bates D., Edan G., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol: 2011; 10 8 745 758
92. Decard B. F., Haghikia A., Tonnes C., et al. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy. Mult Scler: 2013; 19 2 249 251
93. Kuhle J., Gosert R., Bühler R., et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology: 2011; 77 23 2010 2016
94. Blair N. F., Brew B. J., Halpern J. P. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology: 2012; 78 7 507 508
95. Schröder A., Lee D. H., Hellwig K., Lukas C., Linker R. A., Gold R. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol: 2010; 67 11 1391 1394
96. Khatri B. O., Man S., Giovannoni G., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology: 2009; 72 5 402 409
97. Stüve O., Marra C. M., Bar-Or A., et al. Altered CD. 4 + /CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol: 2006; 63 10 1383 1387
98. Hall C. D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med: 1998; 338 19 1345 1351 (Pubitemid 28216663)
99. De Luca A., Ammassari A., Pezzotti P., et al. Gesida 9/99, IRINA, ACTG 363 Study Groups Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS: 2008; 22 14 1759 1767
100. Brickelmaier M., Lugovskoy A., Kartikeyan R., et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother: 2009; 53 5 1840 1849
101. Cettomai D., McArthur J. C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol: 2009; 66 2 255 258
102. Tan I. L., McArthur J. C., Clifford D. B., Major E. O., Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology: 2011; 77 11 1061 1067
103. Metz I., Radue E. W., Oterino A., et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol: 2012; 123 2 235 245
104. Aly L., Yousef S., Schippling S., et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy- immune reconstitution inflammatory syndrome. Brain: 2011; 134 Pt 9 2687 2702
105. Ryschkewitsch C. F., Jensen P. N., Monaco M. C., Major E. O. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol: 2010; 68 3 384 391
106. Vermersch P., Kappos L., Gold R., et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology: 2011; 76 20 1697 1704
107. Clifford D. B., De Luca A., Simpson D. M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol: 2010; 9 4 438 446
108. Bozic C., Belcher G., Kroojimans M., et al. The safety of natalizumab in patients with relapsing multiple sclerosis: an update from TOUCH™ and TYGRIS Paper presented at: 59th Annual Meeting of the American Academy of Neurology.; April 28-May 5, 2007; Boston, MA
109. Gorelik L., Goelz S., Sandrock A. W. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med: 2009; 361 25 2487 2488, author reply 2489-2490
110. Jilek S., Jaquiéry E., Hirsch H. H., et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol: 2010; 9 3 264 272
111. Gorelik L., Lerner M., Bixler S., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol: 2010; 68 3 295 303
112. Bozic C., Richman S., Plavina T., et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol: 2011; 70 5 742 750
113. Trampe A. K., Hemmelmann C., Stroet A., et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology: 2012; 78 22 1736 1742
114. Sorensen P. S., Bertolotto A., Edan G., et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler: 2012; 18 2 143 152
115. Heesen C., Kleiter I., Nguyen F., et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler: 2010; 16 12 1507 1512
116. Tur C., Tintoré M., Vidal-Jordana A., et al. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Mult Scler: 2012; 18 8 1193 1196
117. Goodin D. S., Cohen B. A., O'Connor P., Kappos L., Stevens J. C. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2008; 71 10 766 773
118. Kappos L., Bates D., Hartung H. P., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol: 2007; 6 5 431 441 (Pubitemid 46551850)
119. Leussink V. I., Lehmann H. C., Meyer zu Hörste G., Hartung H. P., Stüve O., Kieseier B. C. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol: 2008; 255 9 1436 1438
120. Hellwig K., Haghikia A., Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler: 2011; 17 8 958 963
121. Hoevenaren I. A., de Vries L. C., Rijnders R. J., Lotgering F. K. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand: 2011; 123 6 430 433
122. Stüve O., Cravens P. D., Frohman E. M., et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology: 2009; 72 5 396 401
123. Rispens T., Vennegoor A., Wolbink G. J., Polman C. H., Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler: 2012; 18 6 899 901
124. Vellinga M. M., Castelijns J. A., Barkhof F., Uitdehaag B. M., Polman C. H. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology: 2008; 70 13 Pt 2 1150 1151 (Pubitemid 351464749)
125. Papeix C., Depaz R., Tourbah A., Stankoff B., Lubetzki C. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult Scler: 2011; 17 12 1520 1522
126. Lenhard T., Biller A., Mueller W., Metz I., Schönberger J., Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology: 2010; 75 9 831 833
127. Kerbrat A., Le Page E., Leray E., et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci: 2011; 308 1-2 98 102
128. Killestein J., Vennegoor A., Strijbis E. M., et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol: 2010; 68 3 392 395
129. O'Connor P. W., Goodman A., Kappos L., et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology: 2011; 76 22 1858 1865
130. Havla J., Gerdes L. A., Meinl I., et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol: 2011; 258 9 1665 1669
131. Magraner M. J., Coret F., Navarré A., et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol: 2011; 258 10 1805 1811
132. Fox R., Kappos L., Cree B., et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. Abstract presented at: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, The Netherlands
133. Rossi S., Motta C., Studer V., et al. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler: 2013; 19 1 59 68